| Cdc53 targets phosphorylated G1 cyclins for degradation by the ubiquitin proteolytic pathway AR Willems, S Lanker, EE Patton, KL Craig, TF Nason, N Mathias, ... Cell 86 (3), 453-463, 1996 | 406 | 1996 |
| Rapid degradation of the G1 cyclin Cln2 induced by CDK-dependent phosphorylation S Lanker, MH Valdivieso, C Wittenberg Science 271 (5255), 1597-1601, 1996 | 314 | 1996 |
| A Saccharomyces cerevisiae homologue of mammalian translation initiation factor 4B contributes to RNA helicase activity. M Altmann, PP Müller, B Wittmer, F Ruchti, S Lanker, H Trachsel The EMBO Journal 12 (10), 3997-4003, 1993 | 190 | 1993 |
| Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+ CD25+ Foxp3 expression in subjects with multiple sclerosis AA Vandenbark, J Huan, M Agotsch, D La Tocha, S Goelz, H Offner, ... Journal of neuroimmunology 215 (1-2), 125-128, 2009 | 117 | 2009 |
| Yeast G1 cyclins are unstable in G1 phase BL Schneider, EE Patton, S Lanker, MD Mendenhall, C Wittenberg, ... Nature 395 (6697), 86-89, 1998 | 107 | 1998 |
| F-box protein Grr1 interacts with phosphorylated targets via the cationic surface of its leucine-rich repeat YG Hsiung, HC Chang, JL Pellequer, R La Valle, S Lanker, C Wittenberg Molecular and cellular biology 21 (7), 2506-2520, 2001 | 97 | 2001 |
| The ISG15 isopeptidase UBP43 is regulated by proteolysis via the SCFSkp2 ubiquitin ligase S Tokarz, C Berset, J La Rue, K Friedman, KI Nakayama, K Nakayama, ... Journal of Biological Chemistry 279 (45), 46424-46430, 2004 | 65 | 2004 |
| Transferable Domain in the G1 Cyclin Cln2 Sufficient To Switch Degradation of Sic1 from the E3 Ubiquitin Ligase SCFCdc4 to SCFGrr1 C Berset, P Griac, R Tempel, J La Rue, C Wittenberg, S Lanker Molecular and cellular biology 22 (13), 4463-4476, 2002 | 64 | 2002 |
| Autoregulation of the yeast lysyl-tRNA synthetase gene GCD5/KRS1 by translational and transcriptional control mechanisms S Lanker, JL Bushman, AG Hinnebusch, H Trachsel, PP Mueller Cell 70 (4), 647-657, 1992 | 64 | 1992 |
| Interactions of the eIF-4F subunits in the yeast Saccharomyces cerevisiae. S Lanker, PP Müller, M Altmann, C Goyer, N Sonenberg, H Trachsel Journal of Biological Chemistry 267 (29), 21167-21171, 1992 | 59 | 1992 |
| SCFGrr1-mediated ubiquitination of Gis4 modulates glucose response in yeast J La Rue, S Tokarz, S Lanker Journal of molecular biology 349 (4), 685-698, 2005 | 19 | 2005 |
| Integrin/chemokine receptor interactions in the pathogenesis of experimental autoimmune encephalomyelitis G Banisadr, SR Schwartz, JR Podojil, LA Piccinini, S Lanker, SD Miller, ... Journal of Neuroimmune Pharmacology 9, 438-445, 2014 | 13 | 2014 |
| Epithelial V-Like Antigen Mediates Efficacy of Anti-Alpha4 Integrin Treatment in a Mouse Model of Multiple Sclerosis E Wright, K Rahgozar, N Hallworth, S Lanker, MD Carrithers PLoS One 8 (8), e70954, 2013 | 13 | 2013 |
| Delayed accumulation of the yeast G1 cyclins Cln1 and Cln2 and the F‐box protein Grr1 in response to glucose JP Fey, S Lanker Yeast 24 (5), 419-429, 2007 | 8 | 2007 |
| Magnetic resonance imaging activity predicts multiple sclerosis patients' response to treatment with interferon beta-1a RP Kinkel, P O'Connor, J Simon, J Carulli, MC Castrillo, S Goelz, R Hyde, ... MULTIPLE SCLEROSIS 14, S51-S51, 2008 | 4 | 2008 |
| Genome-wide mapping of patient autoantibody targets to understand and predict multiple sclerosis pathogenesis and patient responses to interferon beta-1a therapy EB DiCillo, E Kountikov, M Zhu, W Zhang, B Hayward, DE Harlow, ... 37th Congress of the European Committee for Treatment and Research in …, 2021 | 1 | 2021 |
| Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation J Oh, L Airas, D Harrison, E Järvinen, T Livingston, S Lanker, RA Malik, ... Frontiers in Neurology 14, 1319869, 2023 | | 2023 |
| A novel autoantigen discovery platform for the identification of diagnostic and theragnostic autoantibody biomarkers in multiple sclerosis E DiCillo, E Kountikov, M Zhu, S Lanker, D Harlow, W Zhang, B Hayward, ... MULTIPLE SCLEROSIS JOURNAL 29, 1120-1121, 2023 | | 2023 |
| Natalizumab in Patients with Early MS: The STRIVE Study (P3. 186) R Balabanov, J Perumal, R Fox, D Campagnolo, E Dian, S Lanker, J Liu, ... Neurology 82 (10_supplement), P3. 186, 2014 | | 2014 |
| Anti-VLA4-Mediated Inhibition of Humeral Autoimmunity in EAE: Dependence on Epithelial V-Like Antigen Expression (P05. 165) M Carrithers, E Wright, K Rahgozar, N Hallworth, S Lanker Neurology 80 (7 Supplement), P05. 165-P05. 165, 2013 | | 2013 |
Peter P MuellerProfessor Molecular Biology, HZIVerified email at Helmholtz-HZI.de
